9820
Global X China Biotech ETF
NAV as of
4 Week: 6.70 - 7.25
52 Week: 6.59 - 10.13
Latest Closing Price
7.23
Premium / Discount
0
Expense Ratio
0.68%
Investment Objective
The ETF seeks to provide investment results that, before deduction of fees and expenses, closely correspond to the performance of the Solactive China Biotech Index NTR.
Main Fund Characteristics
Performance
| Period | Performance Returns(%) | Volatility(%) | Risk Adjusted Performance |
|---|---|---|---|
| YTD | -15.98 | 1.65 | -9.71 |
| 1 Day | 0.77 | 0.00 | 0.00 |
| 1 Week | 3.21 | 3.68 | 0.87 |
| 1 Month | 3.43 | 7.29 | 0.47 |
| 3 Months | 3.66 | 13.17 | 0.28 |
| 6 Months | -12.73 | 17.93 | -0.71 |
| 1 Year | 0.70 | 30.07 | 0.02 |
| 2 Years | -49.90 | 46.85 | -1.06 |
| 3 Years | 0.00 | 0.00 | 0.00 |
| 5 Years | 0.00 | 0.00 | 0.00 |
| 10 Years | 0.00 | 0.00 | 0.00 |
Price History
Annual Performance Return
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
| Price (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 69.6975 | -19.6517 | -26.0911 |
| Nav (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
| Rank | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 3.0000 | 82.0000 | 85.0000 |
Dividend Frequency
Lastest Dividend
| Ex Date | Payment Date | Dividend Payout per unit |
|---|---|---|
| N.A | ||
Portfolio Data
Total Number of Holdings: 31
Number of Bond Holdings: 0
Number of Equity Holdings: 30
Total Market Value: 555,264,529
Portfolio Composition
Top 10 Holdings
| % Portfolio Weight | Shares Owned | Shares Changed | Market Value | ||
|---|---|---|---|---|---|
| 1 | Wuxi AppTec Co Ltd Class A | 11.4496 | 718,851 | 0 | 63,021,667 |
| 2 | WuXi Biologics (Cayman) Inc | 9.8091 | 1,296,264 | 0 | 53,991,613 |
| 3 | Jiangsu Hengrui Pharmaceuticals Co Ltd Class A | 8.4222 | 1,023,130 | 0 | 46,358,020 |
| 4 | Innovent Biologics Inc | 7.4678 | 1,076,258 | 0 | 41,104,899 |
| 5 | Shanghai RAAS Blood Products Co Ltd Class A | 4.6830 | 3,666,600 | 0 | 25,776,198 |
| 6 | Sino Biopharmaceutical Ltd | 4.0856 | 8,322,763 | 0 | 22,487,983 |
| 7 | Beijing Tiantan Biological Products Corp Ltd Class | 3.6223 | 771,600 | 0 | 19,938,144 |
| 8 | China National Medicines Corp Ltd Class A | 3.0837 | 512,800 | 0 | 16,973,680 |
| 9 | Genscript Biotech Corp Class H | 3.0240 | 853,876 | 0 | 16,645,084 |
| 10 | Zai Lab Ltd ADR Repr 1 Shs | 2.8557 | 85,099 | 0 | 15,718,396 |
Country Exposure
Regional Exposure
America
Greater Europe
Greater Asia
Market Classification
Market Capitalization
| Size | % of portfolio |
|---|---|
| Giant | 29.68 |
| Large | 36.65 |
| Medium | 16.35 |
| Small | 3.02 |
| Micro | 0.00 |
Equity Style Box Breakdown
| 0 | 0 | 0 | Large |
| 0 | 0 | 0 | Mid |
| 0 | 0 | 0 | Small |
| Value | Blend | Growth |
Value Measures
Price/Prospective Earnings*
193.0502
Price/Book*
1.9714
Price/Sales*
9.9533
Price/Cash Flow*
23.6295
Dividend Yield*
0.8713
Growth Measures
Long-Term Earnings
18.3638
Historical Earnings
-5.7444
Sales Growth
10.1425
Cash-Flow Growth
-69.6719
Book-Value Growth
19.7047
*Forward-looking based on historical data.
Equity Sector
Number of Bond Holdings
0
Bond Statitics
| Detail | Value |
|---|---|
| Average Effective Duration | 0 |
| Average Effective Maturity (Years)* | 0 |
| Average Credit Quality | 0 |
| Average Weighted Coupon* | 0 |
| Average Weighted Price* | 0 |
Bond Style Box Breakdown
| 0 | 0 | 0 | High | Quality |
| 0 | 0 | 0 | Med | |
| 0 | 0 | 0 | Low | |
| Ltd | Mod | Ext | ||
| Interest-Rate Sensitivity | ||||
Credit Quality
| Type | % Bonds |
|---|---|
| N.A | |
Bond Sector
Bond Maturity
| % Bonds | |
|---|---|
| N.A | |
Data Source: Morningstar
© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.
Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.
For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.
